Enanta Pharmaceuticals
Enanta Pharmaceuticals' revenue fell 3.6% to $63 million in fiscal 2026. Its operating margin was −99.0%, up from −130.7% a year earlier. Free cash flow was −$43 million. The diluted share count rose 35.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Enanta Pharmaceuticals does
Enanta Pharmaceuticals is a biotechnology company that uses its chemistry and drug discovery skills to develop small molecule drugs, mainly for viral infections and immune diseases. It had 74 full-time employees as of September 30, 2026.
Its revenue comes from royalties. It discovered glecaprevir, an antiviral protease inhibitor that is part of AbbVie's hepatitis C (HCV) treatment sold as MAVYRET in the US and MAVIRET elsewhere. AbbVie sells it, and Enanta earns royalties on those sales.
Its own programs are in two areas. In virology it is focused on respiratory syncytial virus (RSV), a common cause of lung infections in young children and older adults, with a candidate called zelicapavir, and it has a clinical-stage program for the virus that causes COVID-19. In immunology it is developing oral small molecules for type 2 inflammatory diseases such as atopic dermatitis, urticaria and asthma. Enanta has not independently developed any approved product.
Its biggest risks, as it describes them
- It will need substantial additional funding, and may be unable to get it.
- It has had net losses and expects more operating losses.
- Its revenue depends on royalties on AbbVie's sales of the MAVYRET/MAVIRET HCV treatment.
- It faces competition in HCV, RSV and the immune diseases it targets.
- It has limited experience developing and selling drugs on its own.
Income statement
From fiscal 2017 to 2019, earnings per share grew 55.8% a year and net income 61.9% a year, as new shares raised the share count by 8% and diluted each share's earnings. Enanta Pharmaceuticals then lost money in fiscal 2020, 2021, 2022, 2023, 2024, 2025 and 2026.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 249 | 370 | 248 | 189 | 194 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | −26.6x | −11.1x | −11.1x | −4.4x |
| Current ratio | 10.4x | 6.7x | 5.2x | 4.2x | 3.8x |
| Quick ratio | 10.4x | 6.7x | 5.2x | 4.2x | 3.8x |
Cash flow
Projections
Project Enanta Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Enanta Pharmaceuticals says to expect
- Cash runway
Enanta expects that its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2029.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Enanta Pharmaceuticals shares on the open market, and 7 insiders sold $183,168.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 5, 2025 | Jay R. LulyPresident and CEO, Director | Sold | 4,743 | $14.23 | $67,493 | Form 4 |
| Dec 5, 2025 | Yat Sun OrChief Scientific Officer | Sold | 2,390 | $14.23 | $34,010 | Form 4 |
| Dec 5, 2025 | Tara Lynn KiefferChief Product Strategy Officer | Sold | 2,106 | $14.23 | $29,968 | Form 4 |
| Dec 5, 2025 | Brendan LuuChief Business Officer | Sold | 1,394 | $14.23 | $19,837 | Form 4 |
| Dec 5, 2025 | Scott T. RottinghausChief Medical Officer | Sold | 798 | $14.23 | $11,356 | Form 4 |
| Dec 5, 2025 | Harry R. Trout IIISee Remarks | Sold | 542 | $14.23 | $7,713 | Form 4 |
| Dec 5, 2025 | Kathleen S. CappsSee Remarks | Sold | 323 | $14.23 | $4,596 | Form 4 |
| Dec 2, 2025 | Harry R. Trout IIISee Remarks | Sold | 380 | $13.96 | $5,305 | Form 4 |
| Dec 2, 2025 | Kathleen S. CappsSee Remarks | Sold | 207 | $13.96 | $2,890 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −157.6% | −52.7% | −71.4% |
| Altman Z'' | −0.20 | −2.79 | −3.08 |
| Accruals ratio | −8.9% | −19.1% | −9.2% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Enanta Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals | FY26 | −3.6% | −99.0% | −67.9% | — | — | — | |
| Nuvation Bio | FY25 | 699.0% | −338.7% | −288.4% | — | — | — | Compare |
| Fortress Biotech | FY25 | 9.7% | −111.0% | — | −323.7% | — | 6 | Compare |
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | Compare |
| Journey Medical | FY25 | 10.2% | −13.2% | — | −22.4% | — | 5 | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 103 | 207 | 205 | 122 | 97 | 86 | 79 | 68 | 65 | 63 |
| Revenue growth | 16.5% | 101.0% | −0.7% | −40.3% | −20.7% | −11.2% | −8.1% | −14.6% | −3.4% | −3.6% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 58 | 95 | 142 | 137 | 174 | 164 | 164 | 132 | 107 | 88 |
| Operating income | 25 | 88 | 37 | −42 | −110 | −124 | −137 | −122 | −85 | −62 |
| Net income | 18 | 72 | 46 | −36 | −79 | −122 | −134 | −116 | −82 | −68 |
| Diluted EPS (US$) | 0.91 | 3.48 | 2.21 | −1.81 | −3.92 | −5.91 | −6.38 | −5.48 | −3.84 | −2.35 |
| Diluted shares (millions) | 19 | 21 | 21 | 20 | 20 | 21 | 21 | 21 | 21 | 29 |
| Cash flow | ||||||||||
| Cash from operations | 53 | 29 | 71 | 7 | −70 | −85 | −103 | −79 | −19 | −43 |
| Capital expenditure | 2 | 3 | 5 | 1 | 1 | 2 | 9 | 18 | 13 | 0 |
| Free cash flow | 50 | 26 | 66 | 6 | −71 | −87 | −112 | −97 | −32 | −43 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 13 | 16 | 19 | 20 | 21 | 27 | 28 | 27 | 19 | 14 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 224 | 309 | 335 | 387 | 244 | 249 | 370 | 248 | 189 | 194 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 327 | 414 | 490 | 486 | 439 | 375 | 462 | 377 | 281 | 276 |
| Total liabilities | 25 | 20 | 27 | 31 | 39 | 54 | 246 | 248 | 216 | 195 |
| Shareholders' equity | 302 | 394 | 462 | 456 | 399 | 321 | 217 | 129 | 65 | 80 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 23.9% | 42.8% | 17.9% | −34.0% | −112.9% | −143.7% | −173.2% | −179.9% | −130.7% | −99.0% |
| Net margin | 17.2% | 34.8% | 22.6% | −29.5% | −81.4% | −141.3% | −168.9% | −171.6% | −125.4% | −108.3% |
| Free cash flow margin | 48.8% | 12.7% | 32.2% | 4.6% | −72.9% | −100.9% | −141.7% | −143.0% | −49.2% | −67.9% |
| Rule of 40 (growth + FCF margin) | 65.2% | 113.7% | 31.5% | −35.7% | −93.6% | −112.1% | −149.8% | −157.6% | −52.7% | −71.4% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 6.2% | 20.7% | 10.8% | −7.9% | −18.5% | −33.8% | −49.7% | −67.2% | −84.6% | −94.2% |
| Return on assets | 5.8% | 19.4% | 10.3% | −7.4% | −17.1% | −29.9% | −31.9% | −27.7% | −24.9% | −24.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |